Adding ascorbic acid to arsenic trioxide produces limited benefit in patients with acute myeloid leukemia excluding acute promyelocytic leukemia
This phase II clinical trial evaluated the efficacy and safety of combining arsenic trioxide (ATO) with ascorbic acid (AA) in patients with acute myeloid leukemia (AML) excluding acute promyelocytic leukemia (APL). Eleven patients, including elderly individuals unfit for intensive chemotherapy, received intravenous ATO (0.25 mg/kg/day) and AA (1 g/day) for